In Vitro Intrinsic Clearance-Based Optimization of N 3-Phenylpyrazinones as Corticotropin-Releasing Factor-1 (CRF1) Receptor Antagonists
A series of pyrazinone-based heterocycles was identified as potent and orally active corticotropin-releasing factor-1 (CRF1) receptor antagonists. Selected compounds proved efficacious in an anxiety model in rats; however, pharmacokinetic properties were not optimal. In this article, we describe an...
Gespeichert in:
| Veröffentlicht in: | Journal of medicinal chemistry 2009-07, Vol.52 (14), p.4161-4172 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4172 |
|---|---|
| container_issue | 14 |
| container_start_page | 4161 |
| container_title | Journal of medicinal chemistry |
| container_volume | 52 |
| creator | Hartz, Richard A Ahuja, Vijay T Rafalski, Maria Schmitz, William D Brenner, Allison B Denhart, Derek J Ditta, Jonathan L Deskus, Jeffrey A Yue, Eddy W Arvanitis, Argyrios G Lelas, Snjezana Li, Yu-Wen Molski, Thaddeus F Wong, Harvey Grace, James E Lentz, Kimberley A Li, Jianqing Lodge, Nicholas J Zaczek, Robert Combs, Andrew P Olson, Richard E Mattson, Ronald J Bronson, Joanne J Macor, John E |
| description | A series of pyrazinone-based heterocycles was identified as potent and orally active corticotropin-releasing factor-1 (CRF1) receptor antagonists. Selected compounds proved efficacious in an anxiety model in rats; however, pharmacokinetic properties were not optimal. In this article, we describe an in vitro intrinsic clearance-based approach to the optimization of pyrazinone-based CRF1 receptor antagonists wherein sites of metabolism were identified by incubation with human liver microsomes. It was found that the rate of metabolism could be decreased by incorporation of appropriate substituents at the primary sites of metabolism. This led to the discovery of compound 12x, a highly potent (IC50 = 1.0 nM) and selective CRF1 receptor antagonist with good oral bioavailability (F = 52%) in rats and efficacy in the defensive withdrawal anxiety test in rats. |
| doi_str_mv | 10.1021/jm900302q |
| format | Article |
| fullrecord | <record><control><sourceid>acs_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1021_jm900302q</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>f40140134</sourcerecordid><originalsourceid>FETCH-LOGICAL-a189t-7b37409c004f6d33b88dd1cb7804b1640b213db9a5ee7618c65de48ca42de1d53</originalsourceid><addsrcrecordid>eNptkM1KAzEUhYMoWKsL3yAbwS6iN8n8LutgtVCsFHU7ZJJMTWmTMYmL6RP42I5UXLk6cPn4uOcgdEnhhgKjt5tdCcCBfRyhEU0ZkKSA5BiNABgjLGP8FJ2FsIEBooyP0Nfc4jcTvcNzG72xwUhcbbXwwkpN7kTQCi-7aHZmL6JxFrsWP2FOnt-17bdd78XeWGd1wCLgyvlopBtsnbFkpQdPMHaNZ0JG5wnF19VqRid4paXuhgue2ijWzpoQwzk6acU26IvfHKPX2f1L9UgWy4d5NV0QQYsykrzheQKlBEjaTHHeFIVSVDb5ULOhWQINo1w1pUi1zjNayCxVOimkSJjSVKV8jCYHr_QuBK_buvNmJ3xfU6h_Jqz_JhzYqwMrZKg37tPb4bN_uG9vwXEn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>In Vitro Intrinsic Clearance-Based Optimization of N 3-Phenylpyrazinones as Corticotropin-Releasing Factor-1 (CRF1) Receptor Antagonists</title><source>American Chemical Society Journals</source><creator>Hartz, Richard A ; Ahuja, Vijay T ; Rafalski, Maria ; Schmitz, William D ; Brenner, Allison B ; Denhart, Derek J ; Ditta, Jonathan L ; Deskus, Jeffrey A ; Yue, Eddy W ; Arvanitis, Argyrios G ; Lelas, Snjezana ; Li, Yu-Wen ; Molski, Thaddeus F ; Wong, Harvey ; Grace, James E ; Lentz, Kimberley A ; Li, Jianqing ; Lodge, Nicholas J ; Zaczek, Robert ; Combs, Andrew P ; Olson, Richard E ; Mattson, Ronald J ; Bronson, Joanne J ; Macor, John E</creator><creatorcontrib>Hartz, Richard A ; Ahuja, Vijay T ; Rafalski, Maria ; Schmitz, William D ; Brenner, Allison B ; Denhart, Derek J ; Ditta, Jonathan L ; Deskus, Jeffrey A ; Yue, Eddy W ; Arvanitis, Argyrios G ; Lelas, Snjezana ; Li, Yu-Wen ; Molski, Thaddeus F ; Wong, Harvey ; Grace, James E ; Lentz, Kimberley A ; Li, Jianqing ; Lodge, Nicholas J ; Zaczek, Robert ; Combs, Andrew P ; Olson, Richard E ; Mattson, Ronald J ; Bronson, Joanne J ; Macor, John E</creatorcontrib><description>A series of pyrazinone-based heterocycles was identified as potent and orally active corticotropin-releasing factor-1 (CRF1) receptor antagonists. Selected compounds proved efficacious in an anxiety model in rats; however, pharmacokinetic properties were not optimal. In this article, we describe an in vitro intrinsic clearance-based approach to the optimization of pyrazinone-based CRF1 receptor antagonists wherein sites of metabolism were identified by incubation with human liver microsomes. It was found that the rate of metabolism could be decreased by incorporation of appropriate substituents at the primary sites of metabolism. This led to the discovery of compound 12x, a highly potent (IC50 = 1.0 nM) and selective CRF1 receptor antagonist with good oral bioavailability (F = 52%) in rats and efficacy in the defensive withdrawal anxiety test in rats.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm900302q</identifier><language>eng</language><publisher>American Chemical Society</publisher><ispartof>Journal of medicinal chemistry, 2009-07, Vol.52 (14), p.4161-4172</ispartof><rights>Copyright © 2009 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a189t-7b37409c004f6d33b88dd1cb7804b1640b213db9a5ee7618c65de48ca42de1d53</citedby><cites>FETCH-LOGICAL-a189t-7b37409c004f6d33b88dd1cb7804b1640b213db9a5ee7618c65de48ca42de1d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm900302q$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm900302q$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>315,782,786,2767,27083,27931,27932,56745,56795</link.rule.ids></links><search><creatorcontrib>Hartz, Richard A</creatorcontrib><creatorcontrib>Ahuja, Vijay T</creatorcontrib><creatorcontrib>Rafalski, Maria</creatorcontrib><creatorcontrib>Schmitz, William D</creatorcontrib><creatorcontrib>Brenner, Allison B</creatorcontrib><creatorcontrib>Denhart, Derek J</creatorcontrib><creatorcontrib>Ditta, Jonathan L</creatorcontrib><creatorcontrib>Deskus, Jeffrey A</creatorcontrib><creatorcontrib>Yue, Eddy W</creatorcontrib><creatorcontrib>Arvanitis, Argyrios G</creatorcontrib><creatorcontrib>Lelas, Snjezana</creatorcontrib><creatorcontrib>Li, Yu-Wen</creatorcontrib><creatorcontrib>Molski, Thaddeus F</creatorcontrib><creatorcontrib>Wong, Harvey</creatorcontrib><creatorcontrib>Grace, James E</creatorcontrib><creatorcontrib>Lentz, Kimberley A</creatorcontrib><creatorcontrib>Li, Jianqing</creatorcontrib><creatorcontrib>Lodge, Nicholas J</creatorcontrib><creatorcontrib>Zaczek, Robert</creatorcontrib><creatorcontrib>Combs, Andrew P</creatorcontrib><creatorcontrib>Olson, Richard E</creatorcontrib><creatorcontrib>Mattson, Ronald J</creatorcontrib><creatorcontrib>Bronson, Joanne J</creatorcontrib><creatorcontrib>Macor, John E</creatorcontrib><title>In Vitro Intrinsic Clearance-Based Optimization of N 3-Phenylpyrazinones as Corticotropin-Releasing Factor-1 (CRF1) Receptor Antagonists</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>A series of pyrazinone-based heterocycles was identified as potent and orally active corticotropin-releasing factor-1 (CRF1) receptor antagonists. Selected compounds proved efficacious in an anxiety model in rats; however, pharmacokinetic properties were not optimal. In this article, we describe an in vitro intrinsic clearance-based approach to the optimization of pyrazinone-based CRF1 receptor antagonists wherein sites of metabolism were identified by incubation with human liver microsomes. It was found that the rate of metabolism could be decreased by incorporation of appropriate substituents at the primary sites of metabolism. This led to the discovery of compound 12x, a highly potent (IC50 = 1.0 nM) and selective CRF1 receptor antagonist with good oral bioavailability (F = 52%) in rats and efficacy in the defensive withdrawal anxiety test in rats.</description><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNptkM1KAzEUhYMoWKsL3yAbwS6iN8n8LutgtVCsFHU7ZJJMTWmTMYmL6RP42I5UXLk6cPn4uOcgdEnhhgKjt5tdCcCBfRyhEU0ZkKSA5BiNABgjLGP8FJ2FsIEBooyP0Nfc4jcTvcNzG72xwUhcbbXwwkpN7kTQCi-7aHZmL6JxFrsWP2FOnt-17bdd78XeWGd1wCLgyvlopBtsnbFkpQdPMHaNZ0JG5wnF19VqRid4paXuhgue2ijWzpoQwzk6acU26IvfHKPX2f1L9UgWy4d5NV0QQYsykrzheQKlBEjaTHHeFIVSVDb5ULOhWQINo1w1pUi1zjNayCxVOimkSJjSVKV8jCYHr_QuBK_buvNmJ3xfU6h_Jqz_JhzYqwMrZKg37tPb4bN_uG9vwXEn</recordid><startdate>20090723</startdate><enddate>20090723</enddate><creator>Hartz, Richard A</creator><creator>Ahuja, Vijay T</creator><creator>Rafalski, Maria</creator><creator>Schmitz, William D</creator><creator>Brenner, Allison B</creator><creator>Denhart, Derek J</creator><creator>Ditta, Jonathan L</creator><creator>Deskus, Jeffrey A</creator><creator>Yue, Eddy W</creator><creator>Arvanitis, Argyrios G</creator><creator>Lelas, Snjezana</creator><creator>Li, Yu-Wen</creator><creator>Molski, Thaddeus F</creator><creator>Wong, Harvey</creator><creator>Grace, James E</creator><creator>Lentz, Kimberley A</creator><creator>Li, Jianqing</creator><creator>Lodge, Nicholas J</creator><creator>Zaczek, Robert</creator><creator>Combs, Andrew P</creator><creator>Olson, Richard E</creator><creator>Mattson, Ronald J</creator><creator>Bronson, Joanne J</creator><creator>Macor, John E</creator><general>American Chemical Society</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20090723</creationdate><title>In Vitro Intrinsic Clearance-Based Optimization of N 3-Phenylpyrazinones as Corticotropin-Releasing Factor-1 (CRF1) Receptor Antagonists</title><author>Hartz, Richard A ; Ahuja, Vijay T ; Rafalski, Maria ; Schmitz, William D ; Brenner, Allison B ; Denhart, Derek J ; Ditta, Jonathan L ; Deskus, Jeffrey A ; Yue, Eddy W ; Arvanitis, Argyrios G ; Lelas, Snjezana ; Li, Yu-Wen ; Molski, Thaddeus F ; Wong, Harvey ; Grace, James E ; Lentz, Kimberley A ; Li, Jianqing ; Lodge, Nicholas J ; Zaczek, Robert ; Combs, Andrew P ; Olson, Richard E ; Mattson, Ronald J ; Bronson, Joanne J ; Macor, John E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a189t-7b37409c004f6d33b88dd1cb7804b1640b213db9a5ee7618c65de48ca42de1d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hartz, Richard A</creatorcontrib><creatorcontrib>Ahuja, Vijay T</creatorcontrib><creatorcontrib>Rafalski, Maria</creatorcontrib><creatorcontrib>Schmitz, William D</creatorcontrib><creatorcontrib>Brenner, Allison B</creatorcontrib><creatorcontrib>Denhart, Derek J</creatorcontrib><creatorcontrib>Ditta, Jonathan L</creatorcontrib><creatorcontrib>Deskus, Jeffrey A</creatorcontrib><creatorcontrib>Yue, Eddy W</creatorcontrib><creatorcontrib>Arvanitis, Argyrios G</creatorcontrib><creatorcontrib>Lelas, Snjezana</creatorcontrib><creatorcontrib>Li, Yu-Wen</creatorcontrib><creatorcontrib>Molski, Thaddeus F</creatorcontrib><creatorcontrib>Wong, Harvey</creatorcontrib><creatorcontrib>Grace, James E</creatorcontrib><creatorcontrib>Lentz, Kimberley A</creatorcontrib><creatorcontrib>Li, Jianqing</creatorcontrib><creatorcontrib>Lodge, Nicholas J</creatorcontrib><creatorcontrib>Zaczek, Robert</creatorcontrib><creatorcontrib>Combs, Andrew P</creatorcontrib><creatorcontrib>Olson, Richard E</creatorcontrib><creatorcontrib>Mattson, Ronald J</creatorcontrib><creatorcontrib>Bronson, Joanne J</creatorcontrib><creatorcontrib>Macor, John E</creatorcontrib><collection>CrossRef</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hartz, Richard A</au><au>Ahuja, Vijay T</au><au>Rafalski, Maria</au><au>Schmitz, William D</au><au>Brenner, Allison B</au><au>Denhart, Derek J</au><au>Ditta, Jonathan L</au><au>Deskus, Jeffrey A</au><au>Yue, Eddy W</au><au>Arvanitis, Argyrios G</au><au>Lelas, Snjezana</au><au>Li, Yu-Wen</au><au>Molski, Thaddeus F</au><au>Wong, Harvey</au><au>Grace, James E</au><au>Lentz, Kimberley A</au><au>Li, Jianqing</au><au>Lodge, Nicholas J</au><au>Zaczek, Robert</au><au>Combs, Andrew P</au><au>Olson, Richard E</au><au>Mattson, Ronald J</au><au>Bronson, Joanne J</au><au>Macor, John E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Vitro Intrinsic Clearance-Based Optimization of N 3-Phenylpyrazinones as Corticotropin-Releasing Factor-1 (CRF1) Receptor Antagonists</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2009-07-23</date><risdate>2009</risdate><volume>52</volume><issue>14</issue><spage>4161</spage><epage>4172</epage><pages>4161-4172</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>A series of pyrazinone-based heterocycles was identified as potent and orally active corticotropin-releasing factor-1 (CRF1) receptor antagonists. Selected compounds proved efficacious in an anxiety model in rats; however, pharmacokinetic properties were not optimal. In this article, we describe an in vitro intrinsic clearance-based approach to the optimization of pyrazinone-based CRF1 receptor antagonists wherein sites of metabolism were identified by incubation with human liver microsomes. It was found that the rate of metabolism could be decreased by incorporation of appropriate substituents at the primary sites of metabolism. This led to the discovery of compound 12x, a highly potent (IC50 = 1.0 nM) and selective CRF1 receptor antagonist with good oral bioavailability (F = 52%) in rats and efficacy in the defensive withdrawal anxiety test in rats.</abstract><pub>American Chemical Society</pub><doi>10.1021/jm900302q</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-2623 |
| ispartof | Journal of medicinal chemistry, 2009-07, Vol.52 (14), p.4161-4172 |
| issn | 0022-2623 1520-4804 |
| language | eng |
| recordid | cdi_crossref_primary_10_1021_jm900302q |
| source | American Chemical Society Journals |
| title | In Vitro Intrinsic Clearance-Based Optimization of N 3-Phenylpyrazinones as Corticotropin-Releasing Factor-1 (CRF1) Receptor Antagonists |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T18%3A52%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Vitro%20Intrinsic%20Clearance-Based%20Optimization%20of%20N%203-Phenylpyrazinones%20as%20Corticotropin-Releasing%20Factor-1%20(CRF1)%20Receptor%20Antagonists&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Hartz,%20Richard%20A&rft.date=2009-07-23&rft.volume=52&rft.issue=14&rft.spage=4161&rft.epage=4172&rft.pages=4161-4172&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/jm900302q&rft_dat=%3Cacs_cross%3Ef40140134%3C/acs_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |